.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on everyone market.The Eli Lilly-partnered biotech hopes to list on the Nasdaq under the sign "BIOA," according to documentations submitted with the Stocks and Substitution Commission. The business has actually not openly shared an anticipated financial quantity for the offering.The clinical-stage provider promotes lead candidate azelaprag, an orally provided tiny molecule slated to get in stage 2 testing in combo along with semaglutide-- offered through Novo Nordisk under brand name Wegovy for weight-loss-- in the 1st one-half of upcoming year. Semaglutide is actually additionally sold as Ozempic as well as Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is actually designed to incorporate well along with GLP-1 medications, enhancing fat burning while maintaining muscle mass. The investigational drug was actually discovered to be well-tolerated among 265 people across 8 period 1 trials, depending on to BioAge.Previously, BioAge gathered the assistance of Lilly to operate a test integrating azelaprag with the Large Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes mellitus as Mounjaro as well as Zepbound for weight loss. The partners are actually currently conducting a stage 2 test of azelaprag and tirzepatide, along with topline outcomes assumed in the 3rd fourth of 2025.The biotech is actually also preparing a blood insulin level of sensitivity proof-of-concept trial evaluating azelaprag as a monotherapy in the initial one-half of following year to sustain possible indicator development. On top of that, the business organizes to talk to the FDA for approval in the second one-half of 2025 to launch individual testing for an NLRP3 inhibitor targeting metabolic ailments and neuroinflammation.BioAge's anticipated relocate to everyone market complies with a small uptick in prepared biotech IPOs coming from Bicara Rehabs and also Zenas Biopharma. Zooming out, the current IPO yard is actually a "mixed picture," along with high-quality providers still debuting on everyone markets, just in lowered numbers, according to PitchBook.